ArticleJournal of proteome research2009
Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation.
Article in Journal of proteome research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 55 citations in OpenAlex.
- Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges.International journal of molecular sciences · 2023Review
- Ahnak deficiency attenuates high-fat diet-induced fatty liver in mice through FGF21 induction.Experimental & molecular medicine · 2021Article
- Article
- Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport.Frontiers in pharmacology · 2021Article
- Celastrol Protects From Cholestatic Liver Injury Through Modulation of SIRT1-FXR Signaling.Molecular & cellular proteomics : MCP · 2019Article
- Metabolic map of osthole and its effect on lipids.Xenobiotica; the fate of foreign compounds in biological systems · 2018Article
- Rapid changes in Atlantic grey seal milk from birth to weaning - immune factors and indicators of metabolic strain.Scientific reports · 2017Article
- An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.Gastroenterology · 2016Review
- Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.International journal of epidemiology · 2016Review
- Mass Spectrometry-Based Metabolomics Identifies Longitudinal Urinary Metabolite Profiles Predictive of Radiation-Induced Cancer.Cancer research · 2016Article
- Genome- and epigenome-wide association study of hypertriglyceridemic waist in Mexican American families.Clinical epigenetics · 2016Article
- Article
- Enhanced acylcarnitine annotation in high-resolution mass spectrometry data: fragmentation analysis for the classification and annotation of acylcarnitines.Frontiers in bioengineering and biotechnology · 2015Article
- Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.Acta pharmacologica Sinica · 2014Article
- Article
- Metabolomics reveals trichloroacetate as a major contributor to trichloroethylene-induced metabolic alterations in mouse urine and serum.Archives of toxicology · 2013Article
- The metabolomic window into hepatobiliary disease.Journal of hepatology · 2013Review
- Stable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expanding tempol pharmacology.Journal of proteome research · 2013Article
- Metabolomics: an essential tool to understand the function of peroxisome proliferator-activated receptor alpha.Toxicologic pathology · 2013Review
- Applications of metabolomics in cancer research.Journal of carcinogenesis · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Activation of the peroxisome proliferator-activated receptor alpha (PPARalpha) is associated with increased fatty acid catabolism and is commonly targeted for the treatment of hyperlipidemia. To identify latent, endogenous biomarkers of PPARalpha activation and hence increased fatty acid beta-oxidation, healthy human volunteers were given fenofibrate orally for 2 weeks and their urine was profiled by UPLC-QTOFMS. Biomarkers identified by the machine learning algorithm random forests included significant depletion by day 14 of both pantothenic acid (>5-fold) and acetylcarnitine (>20-fold), observations that are consistent with known targets of PPARalpha including pantothenate kinase and genes encoding proteins involved in the transport and synthesis of acylcarnitines. It was also concluded that serum cholesterol (-12.7%), triglycerides (-25.6%), uric acid (-34.7%), together with urinary propylcarnitine (>10-fold), isobutyrylcarnitine (>2.5-fold), (S)-(+)-2-methylbutyrylcarnitine (5-fold), and isovalerylcarnitine (>5-fold) were all reduced by day 14. Specificity of these biomarkers as indicators of PPARalpha activation was demonstrated using the Ppara-null mouse. Urinary pantothenic acid and acylcarnitines may prove useful indicators of PPARalpha-induced fatty acid beta-oxidation in humans. This study illustrates the utility of a pharmacometabolomic approach to understand drug effects on lipid metabolism in both human populations and in inbred mouse models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.